Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience : Episode 2

Opinion

Video

July 31, 2024

Navigating CML: Tools to Empower Patients and Caregivers

Author(s):

Jorge E. Cortes, MD,Joannie Clements

Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment

Now Viewing

EP: 2.Navigating CML: Tools to Empower Patients and Caregivers

EP: 3.Empowering CML Caregivers: Strategies and Support Systems

EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes

EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy

EP: 8.Ensuring Informed CML Care from Diagnosis Onward

EP: 9.Advancing CML Management Towards an Ideal Patient Journey

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
  • What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
    • How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of doctor with text.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Illustration of doctor.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Dr. Richard “Rick" Winneker
Related Content
Advertisement
Image of ribbon
July 2nd 2025

This Wasn’t the Plan: My Mother and Her Silence

Ajay Shanker Mishra
In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared for her daughter while silently battling her own illness.
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
January 15th 2024

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

Alex Biese Brielle Benyon
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
At age 19, stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope: © stock.adobe.com.
June 28th 2025

This Wasn't the Plan: When the World Shifted After Cancer

Ajay Shanker Mishra
At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.
Treating Waldenstrom’s Macroglobulinemia
December 17th 2020

Treating Waldenstrom’s Macroglobulinemia

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
Image of blood.
June 5th 2025

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

Spencer Feldman
Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.
Image of blood cells.
May 27th 2025

Improving Education and Advocacy in Waldenström Macroglobulinemia

Ryan Scott
Education and patient advocacy are essential to improving care in Waldenström macroglobulinemia amid clinical advances, according to Dr. Shirley D'Sa.
Related Content
Advertisement
Image of ribbon
July 2nd 2025

This Wasn’t the Plan: My Mother and Her Silence

Ajay Shanker Mishra
In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared for her daughter while silently battling her own illness.
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
January 15th 2024

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

Alex Biese Brielle Benyon
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
At age 19, stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope: © stock.adobe.com.
June 28th 2025

This Wasn't the Plan: When the World Shifted After Cancer

Ajay Shanker Mishra
At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.
Treating Waldenstrom’s Macroglobulinemia
December 17th 2020

Treating Waldenstrom’s Macroglobulinemia

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
Image of blood.
June 5th 2025

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

Spencer Feldman
Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.
Image of blood cells.
May 27th 2025

Improving Education and Advocacy in Waldenström Macroglobulinemia

Ryan Scott
Education and patient advocacy are essential to improving care in Waldenström macroglobulinemia amid clinical advances, according to Dr. Shirley D'Sa.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.